PFPG
GALT icon

Pinnacle Financial Partners (Georgia)’s Galectin Therapeutics GALT Stock Holding History

Pinnacle Financial Partners (Georgia)’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$193K Hold
41,650
– – ﹤0.01% 1110
2026
Q1 		$116K Sell
41,650
-6,350
-13% -$19.3K ﹤0.01% 1066
2025
Q4 		$200K Buy
+48,000
New +$253K ﹤0.01% 1030

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Pinnacle Financial Partners (Georgia)'s GALT Position: Q2 2026 in Review

Pinnacle Financial Partners (Georgia) held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 41,650 shares worth $193K. The position accounts for ﹤0.01% of the portfolio, ranked #1110.

Pinnacle Financial Partners (Georgia) first reported a position in GALT in Q4 2025 and has held it in 3 quarters since. The position peaked at $200K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Pinnacle Financial Partners (Georgia) held 41,650 shares of Galectin Therapeutics worth $193K as of Q2 2026.
  • Pinnacle Financial Partners (Georgia) left its Galectin Therapeutics share count unchanged in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of Pinnacle Financial Partners (Georgia)'s portfolio in Q2 2026, its #1110 holding.
  • Pinnacle Financial Partners (Georgia) first reported a position in Galectin Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pinnacle Financial Partners (Georgia)'s Galectin Therapeutics position peaked at $200K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Pinnacle Financial Partners (Georgia)'s 13F filing for Q2 2026, filed 14 Aug 2026.